SCHEMBL22658141

SCHEMBL22658141

CCCc1cc(N)cc(-c2ccccc2)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.41
PDE4A P27815 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
BACE1 P56817 2/20 0.37
IKBKB O14920 1/20 0.36
FYN P06241 1/20 0.36
GABRA1 P14867 2/20 0.36
GABRB2 P47870 2/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
DHFR P00374 2/20 0.35
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29408296 1.00 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL22678869 0.83 PDE4B (0.42) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL22678870 0.82 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL22658124 0.82 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DTUBB4A
SCHEMBL29113865 0.82 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL29408241 0.81 PDE4B (0.38) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL22658167 0.81 PDE4B (0.38) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL29795424 0.76 DPP4 (0.41) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL28064439 0.76 FYN (0.50) PDE4BPDE4APDE4CPDE4DFYN
SCHEMBL27398014 0.76 PTGDR2 (0.43) BACE1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO INC (US) 2026-03-26 US disclosed
US-12441689-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2025-10-14 US disclosed
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-03-16 US disclosed
EP-3969439-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF Metabomed Ltd (IL) 2022-03-23 EP disclosed
CN-114127049-A ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2022-03-01 CN disclosed
WO-2020230134-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed
WO-2020230134-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230084752-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 PDE4B 2763/4885PDE4A 2904/4885PDE4C 2971/4885
US-20260085048-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ACSL3 PDE4B 2283/4885PDE4A 2933/4885PDE4C 2890/4885
US-12441689-B2 ACSS2 inhibitors and methods of use thereof ACSS2, ADSS2, GLS2 PDE4B 2763/4885PDE4A 2904/4885PDE4C 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.